STEVAN LAHR: Open Payments
NPI 1740341577 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,420 in 78 payments from 11 companies in 2025. Trend: 2023 $733 · 2024 $1,168 · 2025 $1,420
Food & beverage: $1,420
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 18 | $299 |
| Alkermes, Inc. | 13 | $194 |
| E.R. Squibb & Sons, L.L.C. | 10 | $154 |
| Neurocrine BioSciences, Inc. | 6 | $149 |
| Indivior Inc. | 9 | $141 |
| Vanda Pharmaceuticals Inc. | 3 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Axsome Therapeutics, Inc. | 4 | $89 |
| Braeburn Inc. | 2 | $57 |
Products named: INVEGA SUSTENNA, COBENFY, INGREZZA, SUBLOCADE, ARISTADA, FANAPT, CAPLYTA, Auvelity.
Industry payments across OK — which companies pay providers there.
